Brainomix Achieves Breakthrough with FDA Clearance of e-Lung AI Software

Established market leader in stroke AI imaging receives its first FDA clearance in the lung imaging space. With this expanded foundation of AI-driven healthcare solutions, the Oxford-based company remains committed to driving innovation and delivering impactful advancements in imaging biomarkers.

Brainomix announced FDA 510(k) clearance for its e-Lung AI software, a breakthrough that marks its first FDA clearance in lung imaging and extends the company's AI imaging portfolio beyond stroke. e-Lung is powered by Brainomix's proprietary weighted reticulovascular score (WRVS) imaging biomarker, designed to support earlier diagnosis and clinical assessment in interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF).

Read the full press release on PR Newswire →